Sample
Scroll through a complete example below. It has the same areas, and the same care, as the one we would prepare for you. The data is real in shape but not real in person: every name, identifier and detail that could point to someone has been removed.
What it covers
You see all of it. An executive summary that names your few real priorities. Then the areas behind them: how you metabolise caffeine, alcohol and common medicines; what your blood markers are saying; what you carry and where your ancestry traces; how your body is built for movement and food. It closes with a plan you can act on, safety notes, and a clear account of how each reading was made.
On scope
This analysis is informational and educational, not a medical diagnosis. The pharmacogenomic, carrier and biomarker pages are read from consumer-grade data and are written as starting points to bring to your physician, never as clinical results or instructions to act on. For a clinical reading, ordered and signed by a physician, see Helixir Health.
Precision Genotype Assessment · HG-SAMPLE
Confidential · Genotype-imputed polygenic assessment · Not a diagnostic test
Contents
How to read this report
This is a genotype-based assessment: your DNA is read on an array, imputed to millions of markers, and combined into polygenic risk scores (PRS): a single number summarising how thousands of variants nudge your predisposition up or down relative to a reference population. A high percentile means a stronger genetic tendency, not a diagnosis. Most findings are modifiable through screening and lifestyle. Because it reads common, well-studied variants, not your whole genome, it cannot see rare or structural variants; the complete read is the Helixir Health whole-genome assessment, at helixirhealth.com/assessment.
A plain-language synthesis of this person's own results: the few findings that justify attention, and what to do about them.
This person presents an athletic, low-cardiometabolic-risk genetic baseline. Across 1,300+ polygenic outcomes the great majority read as typical or favourable; the screen surfaces a small number of high-signal findings worth acting on, and several that simply confirm choices already made.
Top findings
Priorities
Lead finding, colorectal predisposition
Top-decile polygenic score, compounded by reported family history. This is the report's primary actionable item: it moves screening earlier than population guidelines.
Favourable cardiovascular ageing
Lower-tertile coronary-risk score, consistent with this person's training load and in-range lipid panel.
Pharmacogenomic note
A genotype associated with favourable lithium response, relevant to continuity of psychiatric care.
A polygenic screen across age-related conditions. For each, your combined genetic signal is compared with a reference population, and we flag where your lifetime predisposition reads as elevated. These are probabilities, not diagnoses, most are modifiable.
Favourable across Cardiovascular ageing · Type 2 diabetes · Inflammatory set-point · Bone density.
Elevated lifetime predisposition. Screening (colonoscopy) is highly effective and brings this back into a manageable range.
Genetic tendency toward hypertension with age. Currently well-controlled by training load; worth periodic monitoring.
Longevity Screener · continued
Higher predisposition to melanoma. Annual dermatology skin checks and sun protection are the key levers.
Also screened · read in the normal range
Alzheimer's Disease
Asthma
Atrial Fibrillation
Bipolar Disorder
Cardiovascular Disease
Celiac Disease
Coronary Artery Disease
Crohn's Disease
Multiple Sclerosis
Osteoporosis
Parkinson's Disease
Rheumatoid Arthritis
Stroke
Type 2 Diabetes
High-range polygenic results (beyond the longevity screen above) with a clear, evidence-based next step. Genetic predisposition is one input among many; screening and lifestyle change outcomes.
Top 8% polygenic risk, compounded by reported family history.
→ Earlier and more frequent colonoscopy screening.
High polygenic load for melanoma.
→ Annual full-skin dermatology review; daily SPF.
Your genotype, summarised by gene into metaboliser phenotypes. This affects how specific drugs are activated or cleared; share this page with any prescriber before a new prescription.
Genotype associated with favourable response.
Normal metaboliser, standard dosing expected.
Phenotypes shown are derived from star-allele (haplotype) calls. Genes marked normal are listed together for completeness.
Bloodwork measured on your own sample, positioned against reference ranges. Genetics shows predisposition; labs show your current biological state.
Liver
Biomarkers · continued
Cardiometabolic
Inflammation
Micronutrients
Recessive conditions where you carry a single variant. This almost never affects your own health; it matters only if both partners carry a variant in the same gene (see Reproductive genetics).
Recessive conditions screened · all clear
Canavan Disease
Familial Mediterranean Fever
Gaucher Disease Type 1
Tay-Sachs Disease
Sickle Cell Anemia
Beta-Thalassemia and Related Hemoglobinopathies
Pompe Disease
Phenylketonuria and Related Disorders
MCAD Deficiency
Maple Syrup Urine Disease Type 1B
Niemann-Pick Disease Type 1A
Usher Syndrome Type 3A
Glycogen Storage Disease Type Ia
Pyruvate Kinase Deficiency
Other inherited conditions · all clear
Your genetic ancestry and your direct maternal (and, where it can be read, paternal) deep lineages. These are heritage, not health: a window into the long path that carried your DNA to you, with no bearing on disease risk. The one medical marker on this page is APOE, the single best-known indicator for long-term brain health, set apart on its own.
Maternal lineage · mtDNA
Haplogroup H1
Western Europe · ~10,000–15,000 years ago
Heritage, not health: a deep-history marker, with no bearing on disease risk or medical guidance.
ε3/ε3
Typical
Two ε3 alleles, the most common genotype, neither protective ε2 nor risk-raising ε4.
Behavioural and sensory tendencies with a partial genetic component. These are traits, not medical findings: included for context and interest, not action.
Higher genetic pull toward sweet foods.
Genetically inclined to wake and perform earlier in the day.
Favourable VO₂-max trainability profile.
The genetics of muscle type, recovery, injury risk and how your body responds to exercise. These are tendencies; training and recovery remain highly modifiable.
Muscle profile
Power-leaning
ACTN3, a power/strength-leaning muscle profile.
Strength training suits this profile.
Nutrigenomics: caffeine and alcohol handling, macronutrient leanings, blood-sugar genes and specific nutrient needs. These shape diet and the supplement formula that follows.
Needs map onto the formula above.
A precision supplement formula built for this person from their genetics, bloodwork and history. Each item carries the main reason it's here: a polygenic nutrient need (PRS), a specific gene (Gene), a need confirmed by bloodwork (Lab), or added for synergy (Cofactor).
Synergistic cofactors
Built for this person from their genetics, bloodwork and history. Each supplement carries the main reason it's here, a polygenic nutrient need (PRS), a specific gene (Gene), a need confirmed by bloodwork (Lab), or added for synergy (Cofactor).
Your Formula · clinician notes & safety
Evidence-based cautions on this specific stack, given everything in this report. The formula is a personalised starting point to review with your own physician or pharmacist; these notes are for that conversation, not self-medication.
Doses here are starting points reasoned for this individual rather than taken from a fixed list. They are informational, not a prescription.
Any supplement–medication interaction is flagged for you to confirm with your own physician before starting.
Nothing here is a prescription. Supplement doses, forms and combinations (and any interaction with prescription medication) should be confirmed with your own physician or pharmacist before you start.
Appendix · Methodology & limitations
DNA was genotyped on an array and statistically imputed to millions of variants. Disease and trait predispositions are expressed as polygenic risk scores(weighted sums of many variants) reported as percentiles against a reference population. Carrier, pharmacogenomic, APOE and ancestry results use direct genotype calls. Findings are then read together rather than in isolation. Where a broad, integrated view of someone’s longevity and a single score point in different directions, the broader view is favoured, and every section is reviewed by hand for the individual.
Limitations
Prepared by
Adriano De Marino, PhD
Lead Genomics · Helixir Genomics
For interpretation within physician-guided care.
How it arrives
You receive two things: a book, printed on heavy paper and bound in cloth, sent to your door, and a digital edition kept in your account. We make it this way on purpose. It is a record you can come back to as your questions change, not a dashboard you log into once and forget. What it reads about you is the point; this is simply a place worth keeping it.
Your turn
What you just scrolled through is the shape of your own analysis. The same areas, filled with your DNA, your labs and your life, and turned into a few clear choices that add up over a lifetime.